Physician profile
Robin R Rash
NPI 1902847353
$948.24
in general payments reported to CMS, 2019-2025
24 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $30.22 · 2021: $139 · 2022: $141 · 2023: $94.92 · 2024: $36.99 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $421.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $157.90 | 2025 | Assure Wcd |
| Pfizer INC. | $96.33 | 2020-2025 | |
| Amgen INC. | $88.61 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $84.06 | 2021 | |
| Lilly USA, LLC | $65.81 | 2021-2025 | Kisunla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.78 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $42.16 | 2025 | Lifevest |
| Merck Sharp & Dohme LLC | $35.91 | 2019-2023 | Vaxneuvance, Vaxelis, Rotateq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.09 | 2019-2025 | Xifaxan |
| Cranial Technologies, INC | $33.06 | 2019-2021 | |
| Corium, LLC | $32.20 | 2023 | Azstarys |
| Abbott Laboratories | $24.98 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.08 | 2022 | |
| Sanofi Pasteur INC. | $20.98 | 2019 | |
| Amarin Pharma, INC. | $19.51 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $17.76 | 2020 | |
| Phadia US INC. | $16.43 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.16 | 2022 | |
| Sunovion Pharmaceuticals INC. | $16.13 | 2022 | |
| Sumitomo Pharma America, INC. | $15.24 | 2025 | Myfembree |
| Genentech USA, INC. | $13.75 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.50 | 2019 | |
| Allergan, INC. | $13.17 | 2019 | |
| Therapeuticsmd, INC. | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Rash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.